Climb Bio Highlights Budoprutug Progress at R&D Spotlight

The latest announcement is out from Climb Bio ( (CLYM) ).

On May 5, 2026, Climb Bio held a virtual R&D Spotlight investor event to showcase progress on budoprutug, its clinical-stage anti-CD19 monoclonal antibody for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus. Management highlighted budoprutug’s Fc-enhanced, high-affinity design, its potential to offer durable B-cell depletion across a range of immune-mediated diseases and the parallel development of both intravenous and subcutaneous formulations.

The company reported positive topline Phase 1 data for the subcutaneous formulation of budoprutug in healthy volunteers, showing robust B-cell depletion comparable to intravenous dosing and a generally safe, well-tolerated profile. Climb Bio said ongoing pMN, ITP and SLE trials are enrolling as planned, with Fast Track designation secured for pMN and initial 2026 readouts expected, including ITP data in June and early pMN and SLE biomarker data in the fourth quarter, underscoring budoprutug’s growing role in its pipeline and potential positioning in B-cell driven autoimmune disease markets.

The most recent analyst rating on (CLYM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.

Spark’s Take on CLYM Stock

According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.

The score is primarily held back by weak financial performance (no revenue, widening losses, and increasing cash burn). Offsetting this are strong technical uptrend signals and a supportive corporate event (the $110M raise improving runway), while valuation remains unfavorable due to ongoing losses.

To see Spark’s full report on CLYM stock, click here.

More about Climb Bio

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying medicines for immune-mediated conditions, including kidney-related diseases. Its pipeline includes budoprutug, an anti-CD19 monoclonal antibody for a broad range of B-cell mediated disorders, and CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy.

The company targets high unmet-need autoimmune indications where B cells are central drivers of pathology, aiming to leverage monoclonal antibody approaches that combine mechanistic precision with scalable delivery. Budoprutug, which has received Orphan Drug and Fast Track designations from the FDA for primary membranous nephropathy, is a core asset in Climb Bio’s strategy to build a portfolio across renal and non-renal immune-mediated diseases.

Average Trading Volume: 656,531

Technical Sentiment Signal: Buy

Current Market Cap: $462.9M

For a thorough assessment of CLYM stock, go to TipRanks’ Stock Analysis page.